Abattis’ Federally Licensed Lab and the Crucial Role It Plays


Ryan Allway

November 1st, 2016

News, Top News


Abattis Bioceuticals (OTC: ATTBF) (CSE: ATT) recently announced the receipt of a Controlled Substance Licence from Health Canada for Northern Vine Laboratories, a company in which Abattis has a 75% stake. The Northern Vine lab site is built, security is in place, and all of the government inspections are complete. Once the lab’s equipment is properly calibrated, Northern Vine will be open for business.

The question to be answered involves the specific nature of that business, the niche it will fill now and going forward, and how the laboratory can benefit Abattis as a whole.

Northern Vine’s Current Business 

Initially, Northern Vine will be providing independent, neutral testing services to Licensed Producers as well as to individuals using medical marijuana under the current regulations. This will be the primary revenue source, and market indications show no shortage of demand for the services. Located in Langley, BC, Northern Vines is in the heart of the Vancouver-area market and will be one of the only testing facilities on the Lower Mainland.

This summer, the Globe and Mail conducted an investigation that found one-third of the samples collected had failed an independent test. In essence, the lack of certified testing labs, and the fact that consumers were not legally allowed to employ testing services, had led to an unsafe and untested black market. Health Canada quickly responded by allowing certified labs to test product brought in by consumers. Concurrently, Health Canada has been cracking down on uncertified testing services.

The new rules create a much larger testing market, and the crackdown has been decreasing the number of places where testing is offered. Northern Vine is stepping into the void with a service that is crucial to both the public safety and to the Licensed Producers looking to offer approved products without investing heavily in their own labs.

Potential Going Forward

Along with the safety testing services, Northern Vine can act as an incubator for product formulations and Intellectual Property development, either contractually for outside companies or for Abattis itself.

Basically, the lab is licensed to handle a controlled substance in Canada, play around and experiment with it, come up with formulas for edibles or medicinals, patent those formulations and introduce them to allowed markets.

Along these lines, Abattis recently announced an MOU with Global Damon Pharma of South Korea. The agreement is initially focused on the distribution of Abattis’ existing PhytoNOS™ and Sassy™ Tonics in South Korea. But establishing this relationship now lays the groundwork for Asian distribution of further products formulated in Canada, in Northern Vine’s lab.

Abattis’ Plan

Northern Vine’s long-anticipated federal license has moved the company from the hypothetical world into the real one. Combined with Abattis’ ownership of its LP application in Quebec called Biocell Labs Inc., and its announcement of an agreement to acquire up to 100% of Experion Biotechnologies Inc., a Licensed Producer applicant in the Vancouver area, these developments reflect a comprehensive long-term plan. If any of the current or future LP applications go through, Abattis will have a production and distribution operation to complement Northern Vine’s testing and product development capabilities.

Abattis’ other established business, Vergence Sales and Marketing, already offers bioceutical products to consumers. With distribution in place and the groundwork being laid for additional Asian channels, Vergence completes the full circle of Abattis’ plan to become a full service legal cannabis operation. From seed to sale, Abattis is putting together a comprehensive business right before our eyes. The market should be noticing these developments long after the pre-election hype dies down.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading